BioSpace News Archive

Spectrum Pharmaceuticals, Inc. completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India.

AAC Holdings, Inc. announced details for the release of its results for the fourth quarter and full year of 2018.

Liht Cannabis Corp. announces Corey Klassen has stepped-down from the Board of Directors to allow for and maintain an appropriate balance of experience and perspectives, with the implementation of changes in the near term.

New clinical data and case studies highlight the use of DiaResQ in a range of real world settings, from hospitals to disaster relief, in its first annual scientific meeting

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA

Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 26, 2019 to file lead plaintiff applications in a securities class action lawsuit against CVS Health Corporation (NYSE: CVS), if they purchased the Company’s securities between May 21, 2015 and February 20, 2019, inclusive (the “Class Period”).

Halo Labs Inc. is pleased to announce that the Company achieved another record setting revenue month in February 2019 of approximately US$2.6MM (CDN $3.4MM).

Horizon Pharma plc announced that the compensation committee of its board of directors approved the grant on March 1, 2018 of inducement restricted stock units for an aggregate of 8,544 ordinary shares to six new employees.

Company is notifying patients and working with local area competitors to shift scheduled surgeries

Synergy Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, confirmed that the previously announced agreement with Bausch Health Companies Inc.